

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95798

Atsuro NAKAZATO, et al.

Appln. No.: 10/584,951

Group Art Unit: 1624

Confirmation No.: 2242

Examiner: Susanna Moore

Filed: September 13, 2006

For: THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED
WITH CYCLIC AMINO GROUP

SUBMISSION OF PRIORITY DOCUMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a certified copy of the priority document on which a claim to
priority was made under 35 U.S.C. § 119. The Examiner is respectfully requested to
acknowledge receipt of said priority document.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

/Susan J. Mack/

Susan J. Mack
Registration No. 30,951

Enclosures: Japan 2004-001310

Date: December 18, 2008

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/JP05/000318

International filing date: 06 January 2005 (06.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: JP
Number: 2004-001310
Filing date: 06 January 2004 (06.01.2004)

Date of receipt at the International Bureau: 03 March 2005 (03.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

04.2.2005

日 本 国 特 許 庁
JAPAN PATENT OFFICE

別紙添付の書類に記載されている事項は下記の出願書類に記載されている事項と同一であることを証明する。

This is to certify that the annexed is a true copy of the following application as filed with this Office.

出 願 年 月 日 2 0 0 4 年 1 月 6 日
Date of Application:


出 願 番 号 特 願 2 0 0 4 - 0 0 1 3 1 0
Application Number:
[ST. 10/C]: [J P 2 0 0 4 - 0 0 1 3 1 0]

出 願 人 大 正 製 薬 株 式 会 社
Applicant(s):

2005年 1月 5日

特許庁長官
Commissioner,
Japan Patent Office

小 川



出証番号 出証特 2 0 0 4 - 3 1 1 9 3 7 1

【書類名】 特許願
【整理番号】 DA-03601
【特記事項】 特許法第36条の2第1項の規定による特許出願
【提出日】 平成16年 1月 6日
【あて先】 特許庁長官殿
【国際特許分類】 C07D419/00
【発明者】
 【住所又は居所】 東京都豊島区高田3丁目24番1号 大正製薬株式会社内
 【氏名】 中里 篤郎
【発明者】
 【住所又は居所】 東京都豊島区高田3丁目24番1号 大正製薬株式会社内
 【氏名】 大久保 武利
【発明者】
 【住所又は居所】 東京都豊島区高田3丁目24番1号 大正製薬株式会社内
 【氏名】 野沢 大
【発明者】
 【住所又は居所】 東京都豊島区高田3丁目24番1号 大正製薬株式会社内
 【氏名】 民田 智子
【発明者】
 【住所又は居所】 ベルギー国、ビールセ、トゥルンホウトセヴェク 30、ヤンセ
 ン ファル マソーティカ エヌ、ヴィー、内
 【氏名】 ケニス、リュド、イー、ジェイ
【特許出願人】
 【識別番号】 000002819
 【氏名又は名称】 大正製薬株式会社
【代理人】
 【識別番号】 100115406
 【弁理士】
 【氏名又は名称】 佐鳥 宗一
【復代理人】
 【識別番号】 100066692
 【弁理士】
 【氏名又は名称】 浅村 皓
【選任した復代理人】
 【識別番号】 100072040
 【弁理士】
 【氏名又は名称】 浅村 肇
【選任した復代理人】
 【識別番号】 100107504
 【弁理士】
 【氏名又は名称】 安藤 克則
【選任した復代理人】
 【識別番号】 100102897
 【弁理士】
 【氏名又は名称】 池田 幸弘
【手数料の表示】
 【予納台帳番号】 002901
 【納付金額】 35,000円
【提出物件の目録】
 【物件名】 外国語特許請求の範囲 1



【物件名】

外国語明細書 1

【物件名】

外国語要約書 1

認定・付加情報

特許出願の番号	特願2004-001310
受付番号	50400012036
書類名	特許願
担当官	笹川 友子 9482
作成日	平成16年 3月31日

<認定情報・付加情報>

【特許出願人】

【識別番号】	000002819
【住所又は居所】	東京都豊島区高田3丁目24番1号
【氏名又は名称】	大正製薬株式会社

【代理人】

【識別番号】	100115406
【住所又は居所】	東京都豊島区高田3丁目24番1号 大正製薬株式会社 知的財産部

【氏名又は名称】	佐島 宗一
----------	-------

【復代理人】

【識別番号】	100066692
【住所又は居所】	東京都千代田区大手町2丁目2番1号 新大手町ビルディング331

【氏名又は名称】	浅村 皓
----------	------

【選任した復代理人】

【識別番号】	100072040
【住所又は居所】	東京都千代田区大手町2丁目2番1号 新大手町ビルディング331

【氏名又は名称】	浅村 肇
----------	------

【選任した復代理人】

【識別番号】	100107504
【住所又は居所】	東京都千代田区大手町2丁目2番1号 新大手町ビルディング331-340

【氏名又は名称】	安藤 克則
----------	-------

【選任した復代理人】

【識別番号】	100102897
【住所又は居所】	東京都千代田区大手町二丁目2番1号 新大手町ビルディング331

【氏名又は名称】	池田 幸弘
----------	-------



[TITLE OF INVENTION]

THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH
CYCLIC AMINO GROUP

5 [DETAILED DESCRIPTION OF THE INVENTION]

[TECHNICAL FIELD]

The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's
10 disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, salpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.

15 [DESCRIPTION OF THE PRIOR ART]

CRF is a hormone comprising 41 amino acids (Science, 213, 1394-1397, 1981; and J. Neurosci., 7, 88-100, 1987), and it is suggested that CRF plays a core role in biological reactions against stresses (Cell. Mol. Neurobiol., 14, 579-588, 1994; Endocrinol., 132, 723-728, 1994; and Neuroendocrinol. 61, 445-452, 1995). For CRF, there are the following two paths: a path by
20 which CRF acts on peripheral immune system or sympathetic nervous system through hypothalamus-pituitary-adrenal system, and a path by which CRF functions as a neurotransmitter in central nervous system (in Corticotropin Releasing Factor: Basic and Clinical Studies of a Neuropeptide, pp. 29-52, 1990). Intraventricular administration of CRF to hypophysectomized rats and normal rats causes an anxiety-like symptom in both types of rats (Pharmacol. Rev., 43,
25 425-473, 1991; and Brain Res. Rev., 15, 71-100, 1990). That is, there are suggested the participation of CRF in hypothalamus-pituitary-adrenal system and the pathway by which CRF functions as a neurotransmitter in central nervous system.

The review by Owens and Nemeroff in 1991 summarizes diseases in which CRF is

involved (Pharmacol. Rev., 43, 425-474, 1991). That is, CRF is involved in depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, inflammation, immunity-related diseases, etc. It has recently been reported that CRF is involved also in epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, and cephalic external wound (Brain Res. 545, 339-342, 1991; Ann. Neurol. 31, 48-498, 1992; Dev. Brain Res. 91, 245-251, 1996; and Brain Res. 744, 166-170, 1997). Accordingly, antagonists against CRF receptors are useful as therapeutic agents for the diseases described above.

10 [PROBLEM(S) TO BE SOLVED BY INVENTION]


An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.

[MEANS FOR SOLVING PROBLEM]


20 The present inventors earnestly investigated thienopyrimidine or thienopyridine derivatives substituted with a cyclic amino group that have a high affinity for CRF receptors, whereby the present invention has been accomplished.

The present invention is thienopyrimidine or thienopyridine derivatives substituted with a cyclic amino group explained below.

25 A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:



5 (wherein the cyclic amino group is represented by the following formula [II]:



10 in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C₁₋₅alkylene or C₁₋₄alkylene-O-C₁₋₄alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by $-(CR^1R^2)_m-(CHR^3)_n-X$, R⁴ and R⁵ independently on the same or different carbon atoms of the cyclic amine;

15 X is cyano or hydroxy;

Y is N or CH;

R¹ is hydrogen, hydroxy, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁₋₅alkyl;

R² is hydrogen or C₁₋₅alkyl;

R³ is hydrogen, cyano, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁₋₅alkyl;

20 m is an integer selected from 0, 1, 2, 3, 4 and 5;

n is 0 or 1;

R⁴ is hydrogen, hydroxy, hydroxy-C₁₋₅alkyl, cyano, cyano-C₁₋₅alkyl or C₁₋₅alkyl;

R^5 is hydrogen or C_{1-5} alkyl;

R⁶ is hydrogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, hydroxy, C₁₋₅alkoxy,

25 C₃₋₈cycloalkyloxy or -N(R⁸)R⁹;

R⁷ is hydrogen, halogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, hydroxy, C₁₋₅alkoxy, C₃₋₈cycloalkyloxy, -N(R¹⁰)R¹¹, -CO₂R¹², cyano, nitro, C₁₋₅alkylthio, trifluoromethyl or trifluoromethoxy;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₅alkoxy, C₁₋₅alkylthio, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and -N(R¹³)R¹⁴;

R⁸ and R⁹ are the same or different, and independently are hydrogen or C₁₋₅alkyl;

R¹⁰ and R¹¹ are the same or different, and independently are hydrogen or C₁₋₅alkyl;

R¹² is hydrogen or C₁₋₅alkyl;

R¹³ and R¹⁴ are the same or different, and independently are hydrogen or C₁₋₅alkyl)

, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

The terms used in the present specification have the following meanings.

The term "a 3- to 8-membered saturated cyclic amine" means aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane.

The term "C₁₋₅alkylene" means a straight or branched chain alkylene of 1 to 5 carbon atoms, such as methylene, ethylene, propylene, trimethylene, tetramethylene, pentamethylene or the like.

The term "a 3- to 8-membered saturated cyclic amine bridged with C₁₋₅alkylene or C₁₋₅alkylene-O-C₁₋₄alkylene between any different two carbon atoms of the cyclic amine" includes, for example, 8-azabicyclo[3.2.1]oct-8-yl, 9-azabicyclo[3.3.1]non-9-yl, 7-azabicyclo[2.2.1]hept-7-yl, 3-oxa-7-azabicyclo[3.3.1]non-7-yl and 3-oxa-9-azabicyclo[3.3.1]non-9-yl.

The term "C₁₋₅alkyl" means a straight chain or branched chain alkyl group of 1 to 5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, *sec*-butyl, pentyl, isopentyl or the like.

The term "C₁₋₅alkoxy" means a straight chain or branched chain alkoxy group of 1 to 5 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutyloxy, pentyloxy, isopentyloxy or the like.

The term "C₁₋₅alkoxy-C₁₋₅alkyl" means a substituted C₁₋₅alkyl group having the above-

mentioned C₁₋₅alkoxy group as the substituent, such as methoxymethyl, 2-methoxyethyl, 2-ethoxyethyl or the like.

The term "hydroxy-C₁₋₅alkyl" means a substituted C₁₋₅alkyl group having hydroxy group, such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl or the like.

The term "cyano-C₁₋₅alkyl" means a substituted C₁₋₅alkyl group having cyano group, such as cyanomethyl, 1-cyanoethyl, 2-cyanoethyl, 3-cyanopropyl, 4-cyanobutyl, 5-cyanopentyl or the like.

The term "C₃₋₈cycloalkyl" means a cyclic alkyl group of 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like.

The term "C₃₋₈cycloalkyl-C₁₋₅alkyl" means a substituted C₁₋₅alkyl group having the above-mentioned C₃₋₈cycloalkyl as the substituent, such as cyclopropylmethyl, cyclopropylethyl, cyclopentylethyl or the like.

The term "C₃₋₈cycloalkyloxy" means a cyclic alkoxy group of 3 to 8 carbon atoms, such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or the like.

The term "halogen" means fluorine, chlorine, bromine or iodine atom.

The term "C₁₋₅alkylthio" means a straight chain or branched chain alkylthio group of 1 to 5 carbon atoms, such as methylthio, ethylthio, propylthio or the like.

The term "aryl" means a monocyclic or bicyclic group of 6 to 12 ring carbon atoms having at least one aromatic ring, such as phenyl, naphthyl, or the like.

The term "heteroaryl" means a monocyclic or bicyclic group of 5 to 12 ring atoms having at least one aromatic ring having in its ring 1 to 4 atoms which may be the same or different and are selected from nitrogen, oxygen and sulfur, such as pyridyl, pyrimidinyl, imidazolyl, quinolyl, indolyl, benzofuranyl, quinoxaliny, benzo[1,2,5]thiadiazolyl, benzo[1,2,5]oxadiazolyl or the like.

The term "C₂₋₅alkenyl" means a straight chain or branched chain alkenyl group of 2 to 5 carbon atoms, such as vinyl, isopropenyl, allyl or the like.

The term "C₂₋₅alkynyl" means a straight chain or branched chain alkynyl group of 2 to 5

carbon atoms, such as ethynyl, prop-1-ynyl, prop-2-ynyl or the like.


The phrase "aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₅alkoxy, C₁₋₅alkylthio, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and -N(R¹³)R¹⁴" includes, for example, 2,4-dimethylphenyl, 2,6-dimethylphenyl, 2,4-dibromophenyl, 2-bromo-4-isopropylphenyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 2-chloro-4-trifluoromethylphenyl, 4-methoxy-2-methylphenyl, 2-chloro-4-trifluoromethoxyphenyl, 4-isopropyl-2-methylthiophenyl, 2,4,6-trimethylphenyl, 4-bromo-2,6-dimethylphenyl, 4-bromo-2,6-diethylphenyl, 4-chloro-2,6-dimethylphenyl, 2,4,6-tribromophenyl, 2,4,5-tribromophenyl, 2,4,6-trichlorophenyl, 2,4,5-trichlorophenyl, 4-bromo-2,6-dichlorophenyl, 6-chloro-2,4-dibromophenyl, 2,4-dibromo-6-fluorophenyl, 2,4-dibromo-6-methylphenyl, 2,4-dibromo-6-methoxyphenyl, 2,4-dibromo-6-methylthiophenyl, 2,6-dibromo-4-isopropylphenyl, 2,6-dibromo-4-trifluoromethylphenyl, 2-bromo-4-trifluoromethylphenyl, 4-bromo-2-chlorophenyl, 2-bromo-4-chlorophenyl, 4-bromo-2-methylphenyl, 4-chloro-2-methylphenyl, 2,4-dimethoxyphenyl, 2,6-dimethyl-4-methoxyphenyl, 4-chloro-2,6-dibromophenyl, 4-bromo-2,6-difluorophenyl, 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-trifluoromethoxyphenyl, 2,6-dibromo-4-trifluoromethoxyphenyl, 2-chloro-4,6-dimethylphenyl, 2-bromo-4,6-dimethoxyphenyl, 2-bromo-4-isopropyl-6-methoxyphenyl, 2,4-dimethoxy-6-methylphenyl, 2,6-dimethyl-4-[2-(2-hydroxyethylamino)ethoxy]phenyl, 6-dimethylamino-4-methylpyridin-3-yl, 2-chloro-6-trifluoromethylpyridin-3-yl, 2-chloro-6-trifluoromethoxypyridin-3-yl, 2-chloro-6-methoxypyridin-3-yl, 6-methoxy-2-trifluoromethylpyridin-3-yl, 2-chloro-6-difluoromethylpyridin-3-yl, 6-methoxy-2-methylpyridin-3-yl, 2,6-dimethoxypyridin-3-yl, 4,6-dimethyl-2-trifluoromethylpyrimidin-5-yl, 2-dimethylamino-6-methylpyridin-3-yl.

The "pharmaceutically acceptable salts" in the present invention include, for example, salts with an inorganic acid such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid or the like; salts with an organic acid such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid,

methanesulfonic acid, *p*-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid or the like; salts with one or more metal ions such as lithium ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc ion, aluminium ion or the like; salts with amines such as ammonia, arginine, lysine, piperazine, choline, diethylamine, 4-phenylcyclohexylamine, 2-aminoethanol, benzathine or the like.

A compound of the present invention includes any isomers such as diastereomers, enantiomers, geometric isomers and tautomeric forms. In a compound represented by formula [I], if the cyclic amino group has one or more chiral carbons and/or if there is an axial chirality between Ar and thienopyrimidine (or thienopyridine) ring, several stereoisomers (diastereomers or enantiomers) can exist. The compound of the present invention includes the individual isomers and the racemic and non-racemic mixtures of the isomers.


Preferable examples of the compound of the present invention are as follows.



20 That is preferable are compounds of the formula [III] in which X, m, n, the cyclic amino group, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and Ar are as defined in claim 1. More preferable are compounds of the formula [III] in which X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0 or 1; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and -N(R¹³)R¹⁴ (wherein R¹³ and R¹⁴ are the same or different, and independently are hydrogen or C₁₋₃alkyl).

Other preferable are compounds of the formula [III] in which X is hydroxy; the cyclic

amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1,2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and -N(R¹³)R¹⁴ (wherein R¹³ and R¹⁴ are the same or different, and independently are hydrogen or C₁₋₃alkyl).



10

Other preferable are compounds of the formula [IV] in which X, m, n, the cyclic amino group, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and Ar are as defined in claim 1. More preferable are compounds of the formula [IV] in which X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0 or 1; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and -N(R¹³)R¹⁴ (wherein R¹³ and R¹⁴ are the same or different, and independently are hydrogen or C₁₋₃alkyl).

15

Other preferable are compounds of the formula [IV] in which X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1,2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and -N(R¹³)R¹⁴ (wherein R¹³ and R¹⁴ are the same or different, and independently are hydrogen or C₁₋₃alkyl).


20

The compound of the formula [I] can be produced, for example, by the process shown in the following reaction scheme 1 (in the following reaction scheme, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, m, n, X, Y and Ar are as defined above, LG is chloro, bromo, iodo, methanesulfonyloxy,

25

benzenesulfonyloxy, toluenesulfonyloxy or trifluoromethanesulfonyloxy group).

Reaction Scheme 1



Step 1:

Compound (3), a compound of the present invention, can be obtained by reacting Compound (1) with Compound (2) in an inert solvent in the presence or absence of a base. Herein, the base includes, for example, amines such as triethylamine, *N,N*-diisopropylethylamine, pyridine and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydroxide, potassium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium *tert*-butoxide and the like; metal amides such as sodium amide, lithium diisopropylamide and the like; and Grignard reagents such as methylmagnesium bromide and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; amides such as *N,N*-dimethylformamide, *N*-methylpyrrolidone, *N,N*-dimethylacetamide and the like; acetonitrile; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.

25 The compound of the present invention can be converted to a salt in an inert solvent with an inorganic acid such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid or the like, with an organic acid such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, *p*-

toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid or the like, with an inorganic base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide, aluminium hydroxide or the like or with an organic base such as ammonia, arginine, lysine, piperazine, choline, diethylamine, 4-phenylcyclohexylamine, 2-aminoethanol, benzathine or the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; esters such as ethyl acetate, ethyl formate and the like; ketones such as acetone, methylethylketone and the like; hydrocarbons such as benzene, toluene and the like; amides such as *N,N*-dimethylformamide, *N*-methylpyrrolidone, *N,N*-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.

The compound of the present invention is useful as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved. For this purpose, the compound of the present invention can be formulated into tablets, pills, capsules, granules, powders, solutions, emulsions, suspensions, injections and the like by a conventional preparation technique by adding conventional fillers, binders, disintegrators, pH-adjusting agents, solvents, etc.

The compound of the present invention can be administered to an adult patient in a dose of 0.1 to 500 mg per day in one portion or several portions orally or parenterally. The dose can be properly increased or decreased depending on the kind of a disease and the age, body weight and symptom of a patient.


[EMBODIMENTS OF THE INVENTION]

The present invention is concretely explained with reference to the following examples and test example, but is not limited thereto.

Example 1

Synthesis of 2-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-


d]pyrimidin-4-yl]-piperidin-4-yl}-ethanol hydrochloride (compound 1-004)



























(1) A mixture of 7-(4-bromo-2,6-dimethylphenyl)-4-chloro-2,6-dimethyl-thieno[3,2-*d*]pyrimidine (500 mg), piperidin-4-ylmethanol (226 mg), *N,N*-diisopropylethylamine (253 mg) in ethanol (1.5 mL) was heated at reflux for 1 day. The reaction mixture was cooled to room temperature, poured into a saturated aqueous sodium hydrogencarbonate, and then extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: hexane/EtOAc = 3 : 1) to obtain 2-{1-[7-(4-bromo-2,6-dimethylphenyl)-2,6-dimethyl-thieno[3,2-*d*]pyrimidin-4-yl]-piperidin-4-yl}-ethanol as a white solid (568 mg).















(2) To a suspension of 2-{1-[7-(4-bromo-2,6-dimethylphenyl)-2,5-dimethyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-piperidin-4-yl}-ethanol (568 mg) in a mixture (1 : 1) of EtOH and EtOAc (2 mL) was added 4 M HCl in EtOAc (0.37 mL) under ice-cooling. The mixture was stirred overnight to afford a white crystal. The crystal was collected by filtration to give the title compound (532 mg).

Table 1 lists the compound obtained in Example 1 and compounds obtained by the similar procedure as in Example 1.

Table 1*¹

Com. No.	Ex. No.	$X-(CR^2R^3)_n-(CHR^1)_m$		Y	R ⁶	R ⁷	-Ar	melting point (°C) (solvent for crystallization)
1-001	1			N	CH ₃	H		amorphous
1-002	1			N	CH ₃	H		amorphous
1-003	1			N	CH ₃	H		177-180* ² (EtOAc/EtOH)
1-004	1			N	CH ₃	CH ₃		242-244* ² (EtOAc/EtOH)
1-005	1			N	CH ₃	H		192-194* ² (EtOH)
1-006	1			N	CH ₃	CH ₃		192-193* ² (EtOAc/EtOH)
1-007	1			N	CH ₃	H		amorphous
1-008	1			N	CH ₃	H		amorphous
1-009	1			N	CH ₃	H		163-165* ² (EtOAc/EtOH)

1-010	1		N	CH ₃	CH ₃		202-204 ^{*2} (EtOAc/EtOH)
1-011	1		CH	CH ₃	H		amorphous
1-012	1		CH	CH ₃	H		amorphous
1-013	1		CH	CH ₃	H		amorphous
1-014	1		CH	CH ₃	H		228-230 ^{*2} (EtOAc/EtOH)
1-015	1		CH	CH ₃	CH ₃		234-236 ^{*2} (EtOAc/EtOH)
1-016	1		CH	CH ₃	H		196-199 ^{*2} (EtOAc/EtOH)
1-017	1		CH	CH ₃	H		231-233 ^{*2} (EtOAc/EtOH)
1-018	1		CH	CH ₃	H		172-174 ^{*2} (EtOAc)
1-019	1		CH	CH ₃	CH ₃		182-184 ^{*2} (EtOAc/EtOH)
1-020	1		CH	CH ₃	H		166-168 ^{*2} (EtOAc/EtOH)
1-021	1		CH	CH ₃	H		158-160 ^{*2} (EtOAc/EtOH)

1-022	1		CH	CH ₃	H		amorphous
1-023	1		CH	CH ₃	H		amorphous
1-024	1		CH	CH ₃	H		amorphous
1-025	1		CH	CH ₃	H		186-188 ^{*2} (EtOAc/IPE)
1-026	1		CH	CH ₃	CH ₃		135-137 ^{*2} (EtOAc/EtOH)
1-027	1		CH	CH ₃	H		179-182 ^{*2} (EtOAc/EtOH)
1-028	1		CH	CH ₃	H		203-205 ^{*2} (EtOAc)

*1: Com. No. = compound number, Ex. No. = example number, solvent for crystallization;

EtOAc = ethyl acetate, EtOH = ethanol, IPE = diisopropylether

Analytical data of non-crystal compounds are described below.

1-001:

- 5 MS (Pos, ES): 408 (M + 1)⁺, 410 (M + 3)⁺, 430 (M + Na)⁺, 432 (M + Na + 2)⁺; NMR (300 MHz, CDCl₃) δ 1.50-2.13 (5 H, m), 2.56 (3H, s), 3.48-3.62 (2H, m), 3.71-4.00 (3 H, m), 4.06-4.29 (2 H, m), 7.35 (1 H, dd, J = 2.0, 8.4 Hz), 7.52 (1 H, d, J = 2.0 Hz), 7.57 (1H, d, J = 8.4 Hz), 7.84 (1 H, s)

10 1-002:

MS (Pos, ES): 408 (M + 1)⁺, 410 (M + 3)⁺; HPLC Retention time: 9.69 (Xterra MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase

A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

5 1-007:

MS (Pos, ES): 436 (M + 1)⁺, 438 (M + 3)⁺; HPLC Retention time: 9.97 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

1-008:

MS (Pos, ES): 403 (M + 1)⁺, 405 (M + 3)⁺; HPLC Retention time: 9.94 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

1-011:

20 MS (Pos, ES): 407 (M + 1)⁺, 409 (M + 3)⁺, 429 (M + Na)⁺, 431 (M + Na + 2)⁺; NMR (300 MHz, CDCl₃) δ 1.20-2.12 (5 H, m), 2.57 (3H, s), 2.80-3.06 (2H, m), 3.52-4.00 (5 H, m), 6.61 (1 H, s), 7.33 (1 H, dd, J = 2.0, 8.4 Hz), 7.51 (1 H, d, J = 2.0 Hz), 7.63 (1H, d, J = 8.4 Hz), 7.73 (1 H, s)

1-012:

25 MS (Pos, ES): 407 (M + 1)⁺, 409 (M + 3)⁺; HPLC Retention time: 10.02 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B

and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

1-013:

- 5 **MS** (Pos, ES): 381 ($M + 1$)⁺; **HPLC** Retention time: 9.22 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

10

1-022:

- MS** (Pos, ES): 409 ($M + 1$)⁺; **HPLC** Retention time: 9.89 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

15

1-023:

- MS** (Pos, ES): 402 ($M + 1$)⁺, 404 ($M + 3$)⁺; **HPLC** Retention time: 6.40 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

20

25 1-024:

- MS** (Pos, ES): 376 ($M + 1$)⁺; **HPLC** Retention time: 6.21 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C:

methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

*2: HCl salt

Test Example [CRF receptor binding test]

Monkey amygdala membranes were used as a receptor preparation.

^{125}I -CRF was used as ^{125}I -labeled ligand.

Binding reaction using the ^{125}I -labeled ligand was carried out by the following method

5 described in The Journal of Neuroscience, 7, 88 (1987).

Preparation of receptor membranes:

Monkey amygdala was homogenized in 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM MgCl_2 , 2 mM EDTA and centrifuged at 48,000 x g for 20 min, and the precipitate was washed once with Tris-HCl buffer. The washed precipitate was suspended in 50 mM Tris-HCl
10 buffer (pH 7.0) containing 10 mM MgCl_2 , 2 mM EDTA, 0.1% bovine serum albumin and 100 kallikrein units/ml aprotinin, to obtain a membrane preparation.

CRF receptor binding test:

The membrane preparation (0.3 mg protein/ml), ^{125}I -CRF (0.2 nM) and a test drug were reacted at 25°C for 2 hours. After completion of the reaction, the reaction mixture was filtered
15 by suction through a glass filter (GF/C) treated with 0.3% polyethylene imine, and the glass filter was washed three times with phosphate-buffered saline containing 0.01% Triton X-100. After the washing, the radioactivity of the filter paper was measured in a gamma counter.

The amount of ^{125}I -CRF bound when the reaction was carried out in the presence of 1 μM CRF was taken as the degree of nonspecific binding of ^{125}I -CRF, and the difference between
20 the total degree of ^{125}I -CRF binding and the degree of nonspecific ^{125}I -CRF binding was taken as the degree of specific ^{125}I -CRF binding. An inhibition curve was obtained by reacting a definite concentration (0.2 nM) of ^{125}I -CRF with various concentrations of each test drug under the conditions described above. A concentration of the test drug at which binding of ^{125}I -CRF is inhibited by 50% (IC_{50}) was determined from the inhibition curve.


25 As a result, it was found that compounds 1-003, 1-004, 1-006, 1-010, 1-012, 1-013, 1-014, 1-015, 1-016, 1-017, 1-018, 1-019, 1-020, 1-021, 1-024, 1-025, 1-026, 1-027 and 1-028 can be exemplified as typical compounds having an IC_{50} value of 100 nM or less.

[EFFECT OF THE INVENTION]


According to the present invention, compounds having a high affinity for CRF receptors have been provided. These compounds are effective against diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, 5 Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.

WHAT IS CLAIMED IS:

1. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:



(wherein the cyclic amino group is represented by the following formula [II]):



in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C₁₋₅alkylene or C₁₋₄alkylene-O-C₁₋₄alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by -(CR¹R²)_m-(CHR³)_n-X, R⁴ and R⁵ independently on the same or different carbon atoms of the cyclic amine;

X is cyano or hydroxy;

Y is N or CH;

R¹ is hydrogen, hydroxy, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁₋₅alkyl;

20 R² is hydrogen or C₁₋₅alkyl;

R³ is hydrogen, cyano, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁₋₅alkyl;

m is an integer selected from 0, 1, 2, 3, 4 and 5;

n is 0 or 1;

R⁴ is hydrogen, hydroxy, hydroxy-C₁₋₅alkyl, cyano, cyano-C₁₋₅alkyl or C₁₋₅alkyl;

25 R⁵ is hydrogen or C₁₋₅alkyl;

R⁶ is hydrogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, hydroxy, C₁₋₅alkoxy, C₃₋₈cycloalkyloxy or -N(R⁸)R⁹;

R⁷ is hydrogen, halogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, hydroxy, C₁₋

salkoxy, C₃₋₈cycloalkyloxy, -N(R¹⁰)R¹¹, -CO₂R¹², cyano, nitro, C₁₋₅alkylthio, trifluoromethyl or trifluoromethoxy;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen,

- 5 C₁₋₅alkyl, C₃₋₈cycloalkyl, C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₅alkoxy, C₁₋₅alkylthio, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and -N(R¹³)R¹⁴;

R⁸ and R⁹ are the same or different, and independently are hydrogen or C₁₋₅alkyl;


R¹⁰ and R¹¹ are the same or different, and independently are hydrogen or C₁₋₅alkyl;

- 10 R¹² is hydrogen or C₁₋₅alkyl;

R¹³ and R¹⁴ are the same or different, and independently are hydrogen or C₁₋₅alkyl)

, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

- 15 2. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [III]:



20

(wherein X, m, n, the cyclic amino group, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.


25

3. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0 or 1; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁-

alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3} alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

4. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3} alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

5. The thienopyridine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [IV]:



25 (wherein X, m, n, the cyclic amino group, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

6. The thienopyridine derivative substituted with the cyclic amino group according to claim 5 represented by formula [IV], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0 or 1; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3} alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
7. The thienopyridine derivative substituted with the cyclic amino group according to claim 5 represented by formula [IV], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3} alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
8. An antagonist for CRF receptors, comprising a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claims 1 to 7, as an active ingredient.
9. Use of a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claim 1 to 7, for the manufacture of an antagonist for CRF receptors.


[ABSTRACT]

[PROBLEM TO BE SOLVED]

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.

[SOLUTION]

A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:



has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

特願2004-001310

出願人履歴情報

識別番号

[000002819]

1. 変更年月日

1990年 8月22日

[変更理由]

新規登録

住所

東京都豊島区高田3丁目24番1号

氏名

大正製薬株式会社